Impact of omalizumab on medical cost of childhood asthma in Japan
Omalizumab is effective in children with severe asthma, but its impact on medical cost in Japan is not clear. We evaluated the impact of omalizumab on medical cost by comparing the pre‐ vs post‐omalizumab‐initiation medical costs of 12 children with severe asthma who received omalizumab for 2 years,...
Gespeichert in:
| Veröffentlicht in: | Pediatrics international 2016-05, Vol.58 (5), p.425-428 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 428 |
|---|---|
| container_issue | 5 |
| container_start_page | 425 |
| container_title | Pediatrics international |
| container_volume | 58 |
| creator | Yoshikawa, Hideki Iwata, Mihoko Matsuzaki, Hiroshi Ono, Rintaro Murakami, Yoko Taba, Naohiko Honjo, Satoshi Motomura, Chikako Odajima, Hiroshi |
| description | Omalizumab is effective in children with severe asthma, but its impact on medical cost in Japan is not clear. We evaluated the impact of omalizumab on medical cost by comparing the pre‐ vs post‐omalizumab‐initiation medical costs of 12 children with severe asthma who received omalizumab for 2 years, and calculating incremental cost‐effectiveness ratio for omalizumab therapy. Health outcome was measured as hospital‐free days (HFD). The median total medical costs and medication fee per patient increased significantly after omalizumab initiation because of the high cost of omalizumab. The median hospitalization fee per patient, however, decreased significantly after omalizumab initiation due to reduction in hospitalization. Omalizumab led to an estimated increase of 40.8 HFD per omalizumab responder patient per 2 years. The cost was JPY 20 868 per additional HFD. Omalizumab can therefore reduce hospitalization cost in children with severe asthma in Japan. |
| doi_str_mv | 10.1111/ped.12936 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811909551</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2172570414</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5426-db02c1e4fb344ff052c690aaf06222301caa54d1f808c686f1b93d888855946e3</originalsourceid><addsrcrecordid>eNqFkU9PFjEQhxujEUQPfgGziRc9LMz0f48E8AVC1INGbk232-Zd3N0u23ej-OktvMDBRJ3LTNJnnmT6I-Q1wj6WOphCu4_UMPmE7CLntKYAl0_LzKiuNUi1Q17kfAUAWmn-nOxQhYpxirvk8GyYnN9UKVZpcH33axlcU6WxGkLbeddXPuW7V7_u-nadUlu5vFkPrurG6txNbnxJnkXX5_Dqvu-Rrx9Ovhyd1hefVmdHhxe1F5zKum2Aegw8NozzGEFQLw04F0FSShmgd07wFqMG7aWWERvDWl1KCMNlYHvk3dY7zel6CXljhy770PduDGnJFjWiASME_h9V2oBghkNB3_6BXqVlHsshlqKiQgFH_i-quLQAA_LW9X5L-TnlPIdop7kb3HxjEextULYEZe-CKuybe-PSlK9-JB-SKcDBFvjR9eHm7yb7-eT4QVlvN7q8CT8fN9z83UrFlLDfPq7sqZDHBlaX9pz9Bjmlp0Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1788509060</pqid></control><display><type>article</type><title>Impact of omalizumab on medical cost of childhood asthma in Japan</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Yoshikawa, Hideki ; Iwata, Mihoko ; Matsuzaki, Hiroshi ; Ono, Rintaro ; Murakami, Yoko ; Taba, Naohiko ; Honjo, Satoshi ; Motomura, Chikako ; Odajima, Hiroshi</creator><creatorcontrib>Yoshikawa, Hideki ; Iwata, Mihoko ; Matsuzaki, Hiroshi ; Ono, Rintaro ; Murakami, Yoko ; Taba, Naohiko ; Honjo, Satoshi ; Motomura, Chikako ; Odajima, Hiroshi</creatorcontrib><description>Omalizumab is effective in children with severe asthma, but its impact on medical cost in Japan is not clear. We evaluated the impact of omalizumab on medical cost by comparing the pre‐ vs post‐omalizumab‐initiation medical costs of 12 children with severe asthma who received omalizumab for 2 years, and calculating incremental cost‐effectiveness ratio for omalizumab therapy. Health outcome was measured as hospital‐free days (HFD). The median total medical costs and medication fee per patient increased significantly after omalizumab initiation because of the high cost of omalizumab. The median hospitalization fee per patient, however, decreased significantly after omalizumab initiation due to reduction in hospitalization. Omalizumab led to an estimated increase of 40.8 HFD per omalizumab responder patient per 2 years. The cost was JPY 20 868 per additional HFD. Omalizumab can therefore reduce hospitalization cost in children with severe asthma in Japan.</description><identifier>ISSN: 1328-8067</identifier><identifier>EISSN: 1442-200X</identifier><identifier>DOI: 10.1111/ped.12936</identifier><identifier>PMID: 27173421</identifier><language>eng</language><publisher>Australia: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Anti-Asthmatic Agents - economics ; Anti-Asthmatic Agents - therapeutic use ; Asthma ; Asthma - drug therapy ; Asthma - economics ; Child ; Childhood ; Children ; Cost-Benefit Analysis ; Drug therapy ; Female ; Health Care Costs - statistics & numerical data ; Health care expenditures ; Hospitalization ; Hospitalization - economics ; Hospitalization - statistics & numerical data ; Humans ; Immunoglobulin E ; Immunotherapy ; Japan ; Male ; medical cost ; Monoclonal antibodies ; omalizumab ; Omalizumab - economics ; Omalizumab - therapeutic use ; Pediatrics ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Pediatrics international, 2016-05, Vol.58 (5), p.425-428</ispartof><rights>2016 Japan Pediatric Society</rights><rights>2016 Japan Pediatric Society.</rights><rights>Copyright © 2016 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5426-db02c1e4fb344ff052c690aaf06222301caa54d1f808c686f1b93d888855946e3</citedby><cites>FETCH-LOGICAL-c5426-db02c1e4fb344ff052c690aaf06222301caa54d1f808c686f1b93d888855946e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fped.12936$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fped.12936$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27173421$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshikawa, Hideki</creatorcontrib><creatorcontrib>Iwata, Mihoko</creatorcontrib><creatorcontrib>Matsuzaki, Hiroshi</creatorcontrib><creatorcontrib>Ono, Rintaro</creatorcontrib><creatorcontrib>Murakami, Yoko</creatorcontrib><creatorcontrib>Taba, Naohiko</creatorcontrib><creatorcontrib>Honjo, Satoshi</creatorcontrib><creatorcontrib>Motomura, Chikako</creatorcontrib><creatorcontrib>Odajima, Hiroshi</creatorcontrib><title>Impact of omalizumab on medical cost of childhood asthma in Japan</title><title>Pediatrics international</title><addtitle>Pediatrics International</addtitle><description>Omalizumab is effective in children with severe asthma, but its impact on medical cost in Japan is not clear. We evaluated the impact of omalizumab on medical cost by comparing the pre‐ vs post‐omalizumab‐initiation medical costs of 12 children with severe asthma who received omalizumab for 2 years, and calculating incremental cost‐effectiveness ratio for omalizumab therapy. Health outcome was measured as hospital‐free days (HFD). The median total medical costs and medication fee per patient increased significantly after omalizumab initiation because of the high cost of omalizumab. The median hospitalization fee per patient, however, decreased significantly after omalizumab initiation due to reduction in hospitalization. Omalizumab led to an estimated increase of 40.8 HFD per omalizumab responder patient per 2 years. The cost was JPY 20 868 per additional HFD. Omalizumab can therefore reduce hospitalization cost in children with severe asthma in Japan.</description><subject>Adolescent</subject><subject>Anti-Asthmatic Agents - economics</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>Asthma</subject><subject>Asthma - drug therapy</subject><subject>Asthma - economics</subject><subject>Child</subject><subject>Childhood</subject><subject>Children</subject><subject>Cost-Benefit Analysis</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Health Care Costs - statistics & numerical data</subject><subject>Health care expenditures</subject><subject>Hospitalization</subject><subject>Hospitalization - economics</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Immunoglobulin E</subject><subject>Immunotherapy</subject><subject>Japan</subject><subject>Male</subject><subject>medical cost</subject><subject>Monoclonal antibodies</subject><subject>omalizumab</subject><subject>Omalizumab - economics</subject><subject>Omalizumab - therapeutic use</subject><subject>Pediatrics</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>1328-8067</issn><issn>1442-200X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9PFjEQhxujEUQPfgGziRc9LMz0f48E8AVC1INGbk232-Zd3N0u23ej-OktvMDBRJ3LTNJnnmT6I-Q1wj6WOphCu4_UMPmE7CLntKYAl0_LzKiuNUi1Q17kfAUAWmn-nOxQhYpxirvk8GyYnN9UKVZpcH33axlcU6WxGkLbeddXPuW7V7_u-nadUlu5vFkPrurG6txNbnxJnkXX5_Dqvu-Rrx9Ovhyd1hefVmdHhxe1F5zKum2Aegw8NozzGEFQLw04F0FSShmgd07wFqMG7aWWERvDWl1KCMNlYHvk3dY7zel6CXljhy770PduDGnJFjWiASME_h9V2oBghkNB3_6BXqVlHsshlqKiQgFH_i-quLQAA_LW9X5L-TnlPIdop7kb3HxjEextULYEZe-CKuybe-PSlK9-JB-SKcDBFvjR9eHm7yb7-eT4QVlvN7q8CT8fN9z83UrFlLDfPq7sqZDHBlaX9pz9Bjmlp0Q</recordid><startdate>201605</startdate><enddate>201605</enddate><creator>Yoshikawa, Hideki</creator><creator>Iwata, Mihoko</creator><creator>Matsuzaki, Hiroshi</creator><creator>Ono, Rintaro</creator><creator>Murakami, Yoko</creator><creator>Taba, Naohiko</creator><creator>Honjo, Satoshi</creator><creator>Motomura, Chikako</creator><creator>Odajima, Hiroshi</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>7TS</scope></search><sort><creationdate>201605</creationdate><title>Impact of omalizumab on medical cost of childhood asthma in Japan</title><author>Yoshikawa, Hideki ; Iwata, Mihoko ; Matsuzaki, Hiroshi ; Ono, Rintaro ; Murakami, Yoko ; Taba, Naohiko ; Honjo, Satoshi ; Motomura, Chikako ; Odajima, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5426-db02c1e4fb344ff052c690aaf06222301caa54d1f808c686f1b93d888855946e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Anti-Asthmatic Agents - economics</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>Asthma</topic><topic>Asthma - drug therapy</topic><topic>Asthma - economics</topic><topic>Child</topic><topic>Childhood</topic><topic>Children</topic><topic>Cost-Benefit Analysis</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Health Care Costs - statistics & numerical data</topic><topic>Health care expenditures</topic><topic>Hospitalization</topic><topic>Hospitalization - economics</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Immunoglobulin E</topic><topic>Immunotherapy</topic><topic>Japan</topic><topic>Male</topic><topic>medical cost</topic><topic>Monoclonal antibodies</topic><topic>omalizumab</topic><topic>Omalizumab - economics</topic><topic>Omalizumab - therapeutic use</topic><topic>Pediatrics</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshikawa, Hideki</creatorcontrib><creatorcontrib>Iwata, Mihoko</creatorcontrib><creatorcontrib>Matsuzaki, Hiroshi</creatorcontrib><creatorcontrib>Ono, Rintaro</creatorcontrib><creatorcontrib>Murakami, Yoko</creatorcontrib><creatorcontrib>Taba, Naohiko</creatorcontrib><creatorcontrib>Honjo, Satoshi</creatorcontrib><creatorcontrib>Motomura, Chikako</creatorcontrib><creatorcontrib>Odajima, Hiroshi</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Physical Education Index</collection><jtitle>Pediatrics international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshikawa, Hideki</au><au>Iwata, Mihoko</au><au>Matsuzaki, Hiroshi</au><au>Ono, Rintaro</au><au>Murakami, Yoko</au><au>Taba, Naohiko</au><au>Honjo, Satoshi</au><au>Motomura, Chikako</au><au>Odajima, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of omalizumab on medical cost of childhood asthma in Japan</atitle><jtitle>Pediatrics international</jtitle><addtitle>Pediatrics International</addtitle><date>2016-05</date><risdate>2016</risdate><volume>58</volume><issue>5</issue><spage>425</spage><epage>428</epage><pages>425-428</pages><issn>1328-8067</issn><eissn>1442-200X</eissn><abstract>Omalizumab is effective in children with severe asthma, but its impact on medical cost in Japan is not clear. We evaluated the impact of omalizumab on medical cost by comparing the pre‐ vs post‐omalizumab‐initiation medical costs of 12 children with severe asthma who received omalizumab for 2 years, and calculating incremental cost‐effectiveness ratio for omalizumab therapy. Health outcome was measured as hospital‐free days (HFD). The median total medical costs and medication fee per patient increased significantly after omalizumab initiation because of the high cost of omalizumab. The median hospitalization fee per patient, however, decreased significantly after omalizumab initiation due to reduction in hospitalization. Omalizumab led to an estimated increase of 40.8 HFD per omalizumab responder patient per 2 years. The cost was JPY 20 868 per additional HFD. Omalizumab can therefore reduce hospitalization cost in children with severe asthma in Japan.</abstract><cop>Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>27173421</pmid><doi>10.1111/ped.12936</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1328-8067 |
| ispartof | Pediatrics international, 2016-05, Vol.58 (5), p.425-428 |
| issn | 1328-8067 1442-200X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1811909551 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adolescent Anti-Asthmatic Agents - economics Anti-Asthmatic Agents - therapeutic use Asthma Asthma - drug therapy Asthma - economics Child Childhood Children Cost-Benefit Analysis Drug therapy Female Health Care Costs - statistics & numerical data Health care expenditures Hospitalization Hospitalization - economics Hospitalization - statistics & numerical data Humans Immunoglobulin E Immunotherapy Japan Male medical cost Monoclonal antibodies omalizumab Omalizumab - economics Omalizumab - therapeutic use Pediatrics Retrospective Studies Treatment Outcome |
| title | Impact of omalizumab on medical cost of childhood asthma in Japan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T08%3A38%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20omalizumab%20on%20medical%20cost%20of%20childhood%20asthma%20in%20Japan&rft.jtitle=Pediatrics%20international&rft.au=Yoshikawa,%20Hideki&rft.date=2016-05&rft.volume=58&rft.issue=5&rft.spage=425&rft.epage=428&rft.pages=425-428&rft.issn=1328-8067&rft.eissn=1442-200X&rft_id=info:doi/10.1111/ped.12936&rft_dat=%3Cproquest_cross%3E2172570414%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1788509060&rft_id=info:pmid/27173421&rfr_iscdi=true |